Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,350.00
-60.00 (-1.11%)
Dec 10, 2025, 3:30 PM KST
-27.36%
Market Cap519.56B
Revenue (ttm)1.96B
Net Income (ttm)-21.96B
Shares Out96.04M
EPS (ttm)-183.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume421,977
Average Volume720,100
Open5,450.00
Previous Close5,410.00
Day's Range5,270.00 - 5,500.00
52-Week Range4,325.00 - 8,225.00
Beta0.96
RSI51.72
Earnings DateNov 28, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.